<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157846">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044758</url>
  </required_header>
  <id_info>
    <org_study_id>RC2AG036419</org_study_id>
    <secondary_id>RC2AG036419</secondary_id>
    <nct_id>NCT01044758</nct_id>
  </id_info>
  <brief_title>Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)</brief_title>
  <official_title>Bridging Cognitive Aging in Rodents to Man Using fMRI in Amnestic MCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to find out if daily use of the drug levetiracetam can improve
      memory function in individuals with memory problems like those associated with Mild
      Cognitive Impairment (MCI) and Alzheimer's disease (AD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increasing research is focused on conditions that precede the clinical diagnosis of
      Alzheimer's disease (AD) in order to detect patients at risk for early intervention. One
      such condition is mild cognitive impairment (MCI). Functional magnetic resonance imaging
      (fMRI) studies in this group of patients have reported increased activation in the MTL
      during performance of memory tasks. The functional significance of increased activation is
      unclear. One possibility is that greater activity reflects the increased effort needed in
      order to maintain performance, and as such would be a compensatory response. An alternative
      possibility is that increased activation reflects aberrant physiology related to the disease
      process itself and as such would be a sign of greater underlying disease severity and would
      interfere with brain function.

      Data in animal models suggest the possibility that low dose levetiracetam (well-tolerated
      anti-convulsant) treatment may reduce the observed hyperactivity and improve memory
      performance among individuals with MCI. We are therefore conducting a within-subjects trial
      of 8 weeks duration, involving 144 subjects and low dose treatment with levetiracetam.
      During the course of the study, each subject may receive both drug and placebo for two
      weeks, with the order of administering those treatments counterbalanced. Cognitive testing
      and fMRI imaging will be obtained after 2-weeks on drug/placebo. The overall goal of the
      study is to determine if treatment of MCI subjects with low dose levetiracetam reduces
      hyperactivity within the MTL and improves memory performance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fMRI activation in medial temporal lobe regions</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Memory performance as assessed in the post-scan procedure and in the neuropsychological test battery</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Mild Cognitive Impairment (MCI)</condition>
  <arm_group>
    <arm_group_label>Amnestic MCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Age matched control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>50mg - 500 mg twice a day for two weeks.</description>
    <arm_group_label>Amnestic MCI</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsule twice a day for two weeks</description>
    <arm_group_label>Amnestic MCI</arm_group_label>
    <arm_group_label>Age matched control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsule twice daily for four weeks</description>
    <arm_group_label>Age matched control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ALL: English as a first language; right handed; able to complete written informed
             consent.

          -  MCI subjects: In addition to above, must meet criteria for amnestic Mild Cognitive
             Impairment (MCI). This includes a memory complaint corroborated by an informant;
             impaired memory function for age and educational level; preserved general cognitive
             function; intact abilities of daily living; no clinical dementia.

          -  Age matched Controls: Must have memory and cognitive status that is normal for their
             age.

        Exclusion Criteria:

          -  Familial Alzheimer's Disease (AD) due to known genetic mutations

          -  AD with Parkinsonian features; major psychiatric or behavioral disorders (e.g.
             depression, agitation, psychosis, manic-depressive disorder)

          -  Primary or metastatic intracranial neoplasm

          -  History of severe head trauma

          -  Intra-cerebral hemorrhage

          -  Seizure disorder

          -  Hemispheric stroke

          -  Presence of a progressive central nervous system disease

          -  Presence of lacunar infarcts

          -  Medical contraindications to MRI including cardiac pacemaker, presence of intraocular
             or intracranial metallic objects

          -  Any known allergy to levetiracetam or behavioral problems that are a contraindication
             to taking Levetiracetam (e.g. agitation)

          -  Prescribed use of anti-seizure medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory L Krauss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008 Sep 19;321(5896):1686-9. doi: 10.1126/science.1162844.</citation>
    <PMID>18802001</PMID>
  </reference>
  <reference>
    <citation>Bakker A, Kirwan CB, Miller M, Stark CE. Pattern separation in the human hippocampal CA3 and dentate gyrus. Science. 2008 Mar 21;319(5870):1640-2. doi: 10.1126/science.1152882.</citation>
    <PMID>18356518</PMID>
  </reference>
  <reference>
    <citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007 Sep 6;55(5):697-711.</citation>
    <PMID>17785178</PMID>
  </reference>
  <reference>
    <citation>Sperling R, Greve D, Dale A, Killiany R, Holmes J, Rosas HD, Cocchiarella A, Firth P, Rosen B, Lake S, Lange N, Routledge C, Albert M. Functional MRI detection of pharmacologically induced memory impairment. Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):455-60. Epub 2001 Dec 26.</citation>
    <PMID>11756667</PMID>
  </reference>
  <reference>
    <citation>Wilson IA, Ikonen S, Gallagher M, Eichenbaum H, Tanila H. Age-associated alterations of hippocampal place cells are subregion specific. J Neurosci. 2005 Jul 20;25(29):6877-86.</citation>
    <PMID>16033897</PMID>
  </reference>
  <reference>
    <citation>Wilson IA, Gallagher M, Eichenbaum H, Tanila H. Neurocognitive aging: prior memories hinder new hippocampal encoding. Trends Neurosci. 2006 Dec;29(12):662-70. Epub 2006 Oct 13. Review.</citation>
    <PMID>17046075</PMID>
  </reference>
  <reference>
    <citation>Koh MT, Haberman RP, Foti S, McCown TJ, Gallagher M. Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. Neuropsychopharmacology. 2010 Mar;35(4):1016-25. doi: 10.1038/npp.2009.207. Epub 2009 Dec 23.</citation>
    <PMID>20032967</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 30, 2012</lastchanged_date>
  <firstreceived_date>January 7, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Gregory Krauss</investigator_full_name>
    <investigator_title>Professor, Neurology-Epilepsy</investigator_title>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Amnestic Mild Cognitive Impairment</keyword>
  <keyword>Functional Magnetic Resonance Imaging</keyword>
  <keyword>Levetiracetam</keyword>
  <keyword>Keppra</keyword>
  <keyword>Medial Temporal Lobe</keyword>
  <keyword>Memory Impairment</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>AD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Mild Cognitive Impairment</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
